Erratum: Endothelial p130cas confers resistance to anti-angiogenesis therapy (Cell Reports (2022) 38(4), (S2211124722000134), (10.1016/j.celrep.2022.110301))

Yunfei Wen, Anca Chelariu-Raicu, Sujanitha Umamaheswaran, Alpa M. Nick, Elaine Stur, Pahul Hanjra, Dahai Jiang, Nicholas B. Jennings, Xiuhui Chen, Sara Corvigno, Deanna Glassman, Gabriel Lopez-Berestein, Jinsong Liu, Mien Chie Hung, Anil K. Sood

Research output: Contribution to journalComment/debatepeer-review

Abstract

(Cell Reports 38, 110301, January 25, 2022) We were made aware of readers’ concerns about potential image duplication in some of the figures from this article, which was originally published with the January 25, 2022 issue. For example, Figures 2C and 2D are described as depicting different proteins on different blots, but there are several seemingly identical regions in the two images, suggesting possible duplication. In Figure S2E, a portion of the image appears as though it may have been duplicated within the image itself. The research integrity office at the authors’ institution was alerted and is investigating these potential issues. The outcome of their investigation will inform any further action that we might take. The purpose of this statement is to inform readers of these concerns and the ongoing investigative process.

Original languageEnglish (US)
Article number112154
JournalCell Reports
Volume42
Issue number3
DOIs
StatePublished - Mar 28 2023

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Erratum: Endothelial p130cas confers resistance to anti-angiogenesis therapy (Cell Reports (2022) 38(4), (S2211124722000134), (10.1016/j.celrep.2022.110301))'. Together they form a unique fingerprint.

Cite this